Skip to main content

Table 2 Best tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

 

mFOLFIRINOX (n = 27)

N (%)

Gemox (n = 22)

N (%)

p value

Complete response

0 (0)

0 (0)

–

Partial response

9 (33.3)

5 (22.7)

–

Stable disease

12 (44.4)

9 (40.9)

–

Progressive disease

6 (22.2)

8 (36.4)

–

Objective response rate

9 (33.3)

5 (22.7)

0.530

Disease control rate

21 (77.8)

14 (63.5)

0.276

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us